Abstract
Overview
The development of pyrimidine and purine antimetabolite drugs has been based on the rationale that nucleic acids are critical to cell replication and, therefore, the pyrimidine and purine bases (and their nucleosides) that are the “building blocks” necessary to synthesize nucleic acids are themselves potential sites for designing drugs that could be effective in inhibiting nucleic acid synthesis, whether that be in bacteria, viruses, or tumor cells. In this chapter, the various antimetabolites or analogs of uracil/thymine, cytidine/deoxycytidine, hypoxanthine/guanine, and adenosine that are currently used in the management of cancer are presented and reviewed with regard to metabolism, mechanism of action, clinical pharmacology, clinical activity, and toxicity.
Reference40 articles.
1. Clinical Pharmacology of 5-Fluorouracil
2. Clinical pharmacokinetics of 5‐fluorouracil and its metabolites in plasma, urine, and bile;Heggie GD;Cancer Res,1987
3. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献